Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta

AIDS. 2006 Jan 9;20(2):297-9. doi: 10.1097/01.aids.0000200535.02232.1b.

Abstract

The use of previously successful antiretroviral regimens in mother-to-child transmission (MTCT) prevention will be increasingly challenged by the rising prevalence of multidrug-resistant (MDR) HIV. We used enfurvitide together with an optimized antiretroviral backbone to prevent the MTCT prevention of MDR HIV in two pregnant women. The measurement of maternal and foetal peripheral blood levels of enfurvitide showed no evidence of transplacental transfer.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Drug Resistance, Multiple, Viral
  • Enfuvirtide
  • Female
  • HIV Envelope Protein gp41 / therapeutic use*
  • HIV Fusion Inhibitors / pharmacokinetics
  • HIV Fusion Inhibitors / therapeutic use
  • HIV Infections / drug therapy*
  • HIV Infections / transmission
  • HIV-1 / drug effects*
  • Humans
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Maternal-Fetal Exchange
  • Peptide Fragments / pharmacokinetics
  • Peptide Fragments / therapeutic use*
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy*

Substances

  • HIV Envelope Protein gp41
  • HIV Fusion Inhibitors
  • Peptide Fragments
  • Enfuvirtide